Dr Albert Sjoerdsma died at his North Carolina home on 27 February 2014 of cardiac arrest after an extended illness. He was 89. Born on 28 August 1924, in Lansing, IL, and raised on a truck farm, Dr Sjoerdsma received a doctorate in pharmacology (1948) and a medical degree (1949) from the University of Chicago. Commissioned in the U.S. Public Health Service from 1951 until 1971, he established the Experimental Therapeutics Branch of the National Heart Institute, retiring with the rank of captain (Medical Director). Dr Sjoerdsma's pioneering work with biogenic amines, initially in collaboration with the laboratories of Dr Sidney Udenfriend, led to the elucidation of serotonin's metabolic degradation to 5-HIAA, discovery of the malignant carcinoid syndrome, elaboration of the clinical and biochemical manifestations of pheochromocytoma, and identification of the mechanism of action of monoamine oxidase inhibitors in humans. His focus on the role of biochemical research in modern drug discovery and development earned him the moniker of 'The Father of Clinical Pharmacology.' Among his therapeutic achievements at the NIH, Dr Sjoerdsma discovered alpha-methyldopa (Aldomet), a breakthrough antihypertensive drug that is still available today. He trained and mentored a generation of clinical pharmacologists, who started academic departments and became known for their own research. I (WML) recall the many hours in Dr Sjoerdsma's office brainstorming about the various research projects ongoing in the lab as the most productive and exciting of my career. We are honored to have known and worked with Dr Sjoerdsma, an outstanding scientist and clinician, and a maverick in research, who was our good friend.
